Research Article | Open Access
Iraj Jafari Anarkooli, Mojtaba Sankian, Shahriar Ahmadpour, Abdol-ReZa Varasteh, Hossein Haghir, "Evaluation of Bcl-2 Family Gene Expression and Caspase-3 Activity in Hippocampus STZ-Induced Diabetic Rats", Journal of Diabetes Research, vol. 2008, Article ID 638467, 6 pages, 2008. https://doi.org/10.1155/2008/638467
Evaluation of Bcl-2 Family Gene Expression and Caspase-3 Activity in Hippocampus STZ-Induced Diabetic Rats
We assessed the expression of Bcl-2 family members at both mRNA and protein levels as well as the Caspase-3 activity, in order to investigate the occurrence of apoptosis in hippocampus of STZ-induced diabetic rats. We selected twenty-four Wistar rats; half of them were made diabetic by intraperitoneal injection of a single 60 mg/kg dose of streptozotocin (STZ, IP), while the others received normal saline and served as controls. The expressions of Bcl-2, , and Bax mRNA and proteins were measured using RT-PCR and western blotting, respectively. Caspases-3 activity was determined by using the Caspase-3/CPP32 Fluorometric Assay Kit. The result showed that mRNA and protein levels of Bcl-2 and were lower in hippocampus of diabetic group than that of the control group, whereas expressions of Bax in hippocampus of diabetic rats were higher than that of controls at both mRNA and protein levels (). Hyperglycemia was found to raise 6.9-fold hippocampal caspase-3 activity in diabetic group compared with control group (). Therefore, the induction of diabetes is associated with increased ratios of Bax/Bcl-2, Bax/, and increased caspase-3 activity in hippocampus which shows that apoptosis is favored in hippocampal region.
Diabetes mellitus is one of the most severe problems global, which is rising significantly. At the present, the WHO accounts 177 million patients with diabetes, while this number is expected to double in 2030 . Diabetes mellitus is a heterogeneous metabolic disorder diagnosed by hyperglycemia resulting from impaired insulin secretion, resistance to insulin action, or both . Hyperglycemia, which occurs under the diabetic condition, is often associated with complications, such as cardiovascular disease, renal failure, retinopathy and peripheral, and autonomic neuropathy [3, 4]. In recent years, it has been suggested that diabetes also affects the central nervous system [5, 6]. Within the central nervous system, the hippocampus is considered as a particular target for changes related to diabetes . Hippocampus is a part of limbic system that serves as a critical integration center for cognitive functions such as learning and memory in the mammalian brain . It has been reported that impairments in memory, learning, and cognition are more common in diabetic people than in nondiabetic ones. In type-1 diabetes mellitus, hippocampal neurons are extremely vulnerable [9–14]. Little is known about the mechanism by which hyperglycemia affects neurons .
Apoptosis could be proposed as a possible mechanism for hyperglycemia-induced hippocampal neuronal cell death. It has been revealed that is apoptosis implicated in several neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis [11, 16]. Apoptosis is a gene-regulated occurrence characterized by special morphological features, including condensation of chromatin, shrinkage of cell and nucleus, membrane blebbing, and DNA fragmentation . Several factors are contributed in apoptosis, but the key elements are categorized in two main families of proteins including caspase enzymes and Bcl-2 family . Caspase enzymes are working as a cascade and caspase 3 is the most important member of this family which plays an effective role in apoptosis of neurons of central nervous system . Bcl-2 family is a set of cytoplasmic proteins that regulate apoptosis. The two main groups of this family, Bcl-2 and Bax proteins, are functionally opposed: Bcl-2 and Bcl-xL act to inhibit apoptosis, whereas Bax counteracts this effect [19, 20].
In this study, we therefore assessed the expression of Bcl-2 family members at both mRNA and protein levels as well as the Caspase-3 activity, in order to investigate the occurrence of apoptosis in hippocampus of STZ-induced diabetic rats.
2. Materials and Methods
We selected twenty-four male Wistar rats weighing (200–250 g) for this study. Animals were randomly divided into two groups ( = 12 in each group): the control (C) and diabetic (D) groups. They were kept in the animal house (Avicenna Research institute, Mashhad University of Medical Sciences, Mashhad, Iran) for one week for proper acclimatization before starting the experiment under controlled condition of illumination (12 hours light/12 hours darkness) and temperature 23 ± 2°C. They were housed under ideal laboratory conditions, maintained on standard pellet diet and water ad libitum throughout the experimental period. All procedures were in accordance with the Guide for the Care and Use of Laboratory Animals of Mashhad University of Medical Sciences, Iran.
Diabetes was induced in overnight fasted experimental group by a single intraperitoneal injection of STZ (Sigma, 60 mg/kg body weight) dissolved in normal saline, while the control group was injected with the normal saline only . Three days after administration of STZ, the tail vein blood glucose level was measured in all animals. Blood glucose levels of 250 mg/dl and above were considered diabetic . At the end of the eighth week, we measured weight and blood glucose level of rats. Then, animals were anesthetized with chloroform and the skull was open along the midline and the brain was removed and placed on an ice-cooled cutting board. The meninges were carefully removed and hippocampus was dissected from hemispheres, snap frozen in liquid nitrogen and stored at −70°C for extraction of DNA, RNA, and protein.
2.1. Isolation of Total RNA and Synthesis of cDNA
RNA was isolated from processed hippocampal tissue of rats using TriPure Isolation Reagent (Roche, Germany) according to the manufacturer instructions. Total RNA was reverse transcribed (RT) into cDNA with MBI RevertAid (Fermentase, Life Sciences, Lithuanian) according to the manufacturers instructions, and cDNA samples were stored at –20°C.
A semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) was carried out to determine the levels of Bcl-2, Bcl-xL, and Bax mRNA expressions. The RT-PCR mixture (final volume of 20 μL) contained 3 μL of cDNA, 10 μL of Qiagen Multiplex PCR Master Mix 2x (Qiagen, Germany) and 10 pmols of each complementary primer specific for Bcl-2, Bcl-xL, and Bax sequences as well as for GAPDH (Glyceraldehydes-3-phosphate dehydrogenase; GAPDH gene) sequence as an internal control (Table 1). The samples were denatured at 95°C for 15 minutes, and amplified using 40 cycles of 95°C for 30 seconds, 60°C for 80 seconds, and 72°C for 45 seconds for Bax gene and 5 cycles of 95°C for 30 seconds, 62°C for 60 seconds, and 72°C for 30 seconds, as well as 25 cycles of 95°C for 30 seconds, 64°C for 80 seconds and 72°C for 30 seconds for Bcl-2 and Bcl-xL genes followed by a final elongation at 72°C for 3 minutes on a Corbett Research thermocycler (Sydney, Australia). The optimal numbers of cycles have been selected for amplification of all three genes experimentally so that amplifications were in the exponential range and have not reached a plateau. Five microliters of the final amplification product were run on a 3% ethidium-stained agarose gel and photographed. Quantification of the results was accomplished by measuring the optical density of the labeled bands, using the computerized imaging program Kodack-1D (USA). The values were normalized to GAPDH intensity levels.
3. Western Blot Analysis
Tissues collected were homogenized with ice-cold homogenizing buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, and 0.5 mM Triton X-100, PH 7.4) and protease inhibitor cocktail tablets (Roche, Germany). Proteins were measured with Bio-Rad protein assay method. Hippocampal protein lysates (50 μg/well) were separated by SDS-PADE (12.5%) under reducing conditions and transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, USA). Membranes were treated with Attoglow western blot system kit, according to the manufacturer protocol (Biochain, USA). Briefly, blots were blocked with blocking buffer (5% not-fat dried milk in PBS). After blocking, blots were incubated with anti-Bcl-2 polyclonal antibody (1/500, v/v), anti-Bcl-xL polyclonal antibody (1/1000, v/v), and anti-Bax polyclonal antibody (1/250, v/v) (Biovision, USA) for 20 hours at 4°C. Blots were washed for 4 times with 0.1% tween 20 in PBS and incubated with HRP conjugated-secondary antibody (1/5000, v/v, Biochain, USA) for 1 hour at room temperature. The Bcl-2, Bcl-xL and Bax protein bands were visualized using enhanced chemiluminescnces (ECL) method (Bioimaging, system, syngene, UK).
4. Detection of Caspase-3 Activity
Caspase-3 activity was determined using the Caspase-3/CPP32 Fluorometric Assay Kit (K105) purchased from Biovision, Inc. (Mountain View, Calif., USA). For each assay, 50 g of tissue cell lysate was used. Samples were read in a fluorimeter equipped (Jasco, FP-6200, Japan) witha 400-nm excitation and a 505-nm emission filter. Fold-increasein Caspase-3 activity was determined by comparing fluorescence of 7-amino-4-trifluoromethyl coumarin in control and treated hippocampus with STZ.
5. Statistical Analyses
All results are evaluated using the The results were analyzed with Mann-Whitney and paired t-tests. A probability level of P <.05 was considered significant.
Blood glucose concentrations of diabetic rats were more than 250 mg/dl 3 days after the administration of STZ. Blood glucose level at the end of the 8th week was significantly increased in diabetic group compared to nondiabetic (control) group ().
At first, both groups had similar body weights. Body weight was increased in the control group at the end of 8 weeks; however, the diabetic groups lost body weight compared to the control ones () (Table 2).
** versus control.
6.1. Expression of Bax, Bcl-2 and Bcl- Genes at mRNA Level
As shown in Figure 1, expression of Bax was increased in the hippocampus of STZ-induced diabetic group compared to that of control group, while the expressions of Bcl-2 and Bcl-xL were reduced. Furthermore, the Bax/Bcl-2 and the Bax/Bcl-xL ratios were increased in the hippocampus of STZ-induced diabetic group compared to control group (Figures 2(a) and 2(b)).
6.2. Expressions of Bax, Bcl-2, and Bcl- Proteins
After eight weeks, the expression of proapoptotic Bax protein was enhanced in hippocampus of STZ-induced diabetic group compared to control group of rats. On the other hand, the expression of anti-apoptotic Bcl-2 and Bcl-xL proteins were decreased in hippocampus of STZ-induced diabetic group compared to the control group of rats (Figure 3).
6.3. Evaluation of Caspase-3 Activity in Tissue Extracts
Caspase-3 activity was significantly higher in STZ-induced diabetic group compared to that of nondiabetic group (174.2 ± 36 versus 25 ± 10.25, ). Hyperglycemia was found to increase 6.9-fold hippocampal tissue caspase-3 activity in diabetic group compared with nondiabetic group (Figure 4).
Despite of extensive investigations, the mechanism(s) activating apoptotic pathways in the diabetic brain have not been completely understood . In the present study, we showed the effects of hyperglycemia on the expression of Bcl-2 family protein levels and Caspase-3 activity in hippocampus of STZ-induced diabetic rats.
Our results showed that after 8 weeks, Bax expression was considerably increased in hippocampus of STZ-induced diabetic rats at both mRNA and protein levels, while the expressions of Bcl-2 and Bcl-xL were significantly reduced at both mRNA and protein levels. Furthermore, Bax/Bcl-2 and Bax/Bcl-xL ratios, a main index of apoptotic cell death, were significantly increased; signifying hyperglycemia-induced apoptosis in hippocampus of STZ-induced diabetic rats could possibly be mediated by the mitochondrial pathway .
Other studies have demonstrated that diabetes induces apoptosis in central nervous system as well as in neuronal-related tissues, including peripheral nervous system, ganglions, and retina [11, 25, 26]. Several experimental models support that overexpression of Bax can induce apoptosis in cells both in vivo and in vitro [11, 27]. In addition, the apoptosis has been reported in neuroblast cell cultures treated with diabetic human sera . Sharifi et al. showed that the excess concentration of glucose resulted in an increase in Bax expression protein and then induced apoptosis in PC12 cells . Apoptosis and decrease in Bcl-2 expression were detected in primary neurons of dorsal root ganglion of spinal cord in diabetic rats [29, 30].
In this study, we were able to reveal the activation of proapoptotic proteins and suppression of antiapoptotic proteins in hippocampus of STZ-induced diabetic rats at both mRNA and protein levels. There are two classes of regulatory proteins in Bcl-2 family that substantiate opposite effects on apoptosis: the antiapoptotic members including Bcl-2 and Bcl-xL which protect cells against some forms of apoptosis, and proapoptotic members including Bax, bak, and Bcl-xS which progress programmed cell death. Apoptotic signals converge toward a common death pathway, for which caspases perform apoptosis and the Bcl-2 family proteins regulate it . There is an absolute evidence that three main signals cause the release of apoptogenic mitochondrial mediators including a proapoptotic member of the Bcl-2 family, elevated level of intracellular calcium, and reactive oxygen species (ROS) or free radicals . It has previously been revealed that both ROS and Nitric Oxide (NO) can change mitochondrial membrane potential by opening the mitochondrial permeability transition pores (mPTP), releasing cytochrome C and subsequent activation of caspases 9 and 3 and finally causing cell death. Members of the Bcl-2 family are known to be pro- and anti-apoptotic. The balance between pro- and anti-apoptotic signals from this family has a central role in the release of cytochrome C and its succeeding consequences .
Furthermore, we found that the activity of caspases-3, an effector of apoptosis that plays a key role to link the commitment and degradation phases , was significantly increased in hippocampus of STZ-induced diabetic rats compared to nondiabetic rats, which is consistent with previous studies [35–38].
Concurrent with our findings, Vincent et al. showed that hyperglycemia observed in diabetes mellitus was associated with oxidative stress-induced neuronal and Schwann cells death via increased caspase 3 activity .
The precise mechanism through which this occurs in hyperglycemia-induced apoptosis is not clear, but it has shown that hyperglycemia could elevate ROS in hippocampal neuronal cells resulted in elevation of intracellular calcium in neuronal cells . Russell et al. showed excess mitochondrial ROS due to hyperglycemia depolarize mitochondrial membranes followed by decrease in ATP activity and increase in Caspases-3 and 9 leading to Caspase-dependent apoptosis . Therefore, the induction of diabetes is associated with increased ratios of Bax/Bcl-2 and Bax/Bcl-xL as well as increase of caspase-3 activity in hippocampus which shows that apoptosis is favored in hippocampal region. In our experiment we also alternative methods such as, silver staining for dark neurons, stereology, electron microscopy and DNA laddering to support the results that obtained with Bcl-2 family gene expression and caspase-3 activity (Unpublished).
Taking together, it may finally be concluded that the STZ-induced hyperglycemia causes hippocampal neuronal cell death, in which apoptosis plays an important role possibly by an increment in the Bax/Bcl-2 and Bax/Bcl-xL ratio, as well as increasing caspase-3 activity. Diabetic-induced memory and cognition deficits may be partly due to a facilitation of apoptosis and this study provide further knowledge to mechanisms involved in STZ-induced apoptosis in hippocampus.
Grant support was provided by Mashhad University of Medical Sciences (MUMS) (no. 85146).
- O. Khookhor, Q. Bolin, Y. Oshida, and Y. Sato, “Effect of Mongolian plants on in vivo insulin action in diabetic rats,” Diabetes Research and Clinical Practice, vol. 75, no. 2, pp. 135–140, 2007.
- J. R. Gavin III, K. G. M. M. Alberti, M. B. Davidson et al., “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 26, supplement 1, pp. S5–S20, 2003.
- G. J. Biessels, L. P. Van der Heide, A. Kamal, R. L. A. Bleys, and W. H. Gispen, “Ageing and diabetes: implications for brain function,” European Journal of Pharmacology, vol. 441, no. 1-2, pp. 1–14, 2002.
- E. L. Feldman, “Oxidative stress and diabetic neuropathy: a new understanding of an old problem,” The Journal of Clinical Investigation, vol. 111, no. 4, pp. 431–433, 2003.
- G.-J. Biessels, A. Kamal, I. J. A. Urban, B. M. Spruijt, D. W. Erkelens, and W. H. Gispen, “Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment,” Brain Research, vol. 800, no. 1, pp. 125–135, 1998.
- R. Stewart and D. Liolitsa, “Type 2 diabetes mellitus, cognitive impairment and dementia,” Diabetic Medicine, vol. 16, no. 2, pp. 93–112, 1999.
- R. A. Harris, International Review of Neurobiology: Glucose Metabolism in the Brain (Glucose, Stress, and Hippocampal Neuronal Vulnerability), Elsevier Science, Alton, Ill, USA, 2002.
- L. P. Reagan, “Insulin signaling effects on memory and mood,” Current Opinion in Pharmacology, vol. 7, no. 6, pp. 633–637, 2007.
- W. H. Gispen and G.-J. Biessels, “Cognition and synaptic plasticity in diabetes mellitus,” Trends in Neurosciences, vol. 23, no. 11, pp. 542–549, 2000.
- C. M. Ryan, “Neurobehavioral complications of type I diabetes. Examination of possible risk factors,” Diabetes Care, vol. 11, no. 1, pp. 86–93, 1988.
- Z.-G. Li, W. Zhang, G. Grunberger, and A. A. Sima, “Hippocampal neuronal apoptosis in type 1 diabetes,” Brain Research, vol. 946, no. 2, pp. 221–231, 2002.
- M. Muriach, F. Bosch-Morell, G. Alexander et al., “Lutein effect on retina and hippocampus of diabetic mice,” Free Radical Biology & Medicine, vol. 41, no. 6, pp. 979–984, 2006.
- L. P. Reagan, A. M. Magariños, and B. S. McEwen, “Neurological changes induced by stress in streptozotocin diabetic rats,” Annals of the New York Academy of Sciences, vol. 893, no. 1, pp. 126–137, 1999.
- C. M. Ryan and T. M. Williams, “Effects of insulin-dependent diabetes on learning and memory efficiency in adults,” Journal of Clinical and Experimental Neuropsychology, vol. 15, no. 5, pp. 685–700, 1993.
- A. M. Sharifi, S. H. Mousavi, M. Farhadi, and B. Larijani, “Study of high glucose-induced apoptosis in PC12 cells: role of bax protein,” Journal of Pharmacological Sciences, vol. 104, no. 3, pp. 258–262, 2007.
- P. C. Waldmeier and W. G. Tatton, “Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?” Drug Discovery Today, vol. 9, no. 5, pp. 210–218, 2004.
- A. H. Wyllie, “Apoptosis: an overview,” British Medical Bulletin, vol. 53, no. 3, pp. 451–465, 1997.
- N. A. Thornberry and Y. Lazebnik, “Caspases: enemies within,” Science, vol. 281, no. 5381, pp. 1312–1316, 1998.
- G. Kroemer, “The proto-oncogene Bcl-2 and its role in regulating apoptosis,” Nature Medicine, vol. 3, no. 6, pp. 614–620, 1997.
- A. Ashkenazi and V. M. Dixit, “Death receptors: signaling and modulation,” Science, vol. 281, no. 5381, pp. 1305–1308, 1998.
- T. Suanarunsawat, S. Klongpanichapak, and N. Chaiyabutr, “Role of nitric oxide in renal function in rats with short and prolonged periods of streptozotocin-induced diabetes,” Diabetes, Obesity and Metabolism, vol. 1, no. 6, pp. 339–346, 1999.
- J. T. Jaouhari, H. B. Lazrek, and M. Jana, “The hypoglycemic activity of Zygophyllum gaetulum extracts in alloxan-induced hyperglycemic rats,” Journal of Ethnopharmacology, vol. 69, no. 1, pp. 17–20, 2000.
- Z.-G. Li, M. Britton, A. A. F. Sima, and J. C. Dunbar, “Diabetes enhances apoptosis induced by cerebral ischemia,” Life Sciences, vol. 76, no. 3, pp. 249–262, 2004.
- M. R. Duchen, “Mitochondria in health and disease: perspectives on a new mitochondrial biology,” Molecular Aspects of Medicine, vol. 25, no. 4, pp. 365–451, 2004.
- A. J. Barber, E. Lieth, S. A. Khin, D. A. Antonetti, A. G. Buchanan, and T. W. Gardner, “Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin,” The Journal of Clinical Investigation, vol. 102, no. 4, pp. 783–791, 1998.
- Z.-G. Li, W. Zhang, and A. A. F. Sima, “C-peptide prevents hippocampal apoptosis in type 1 diabetes,” International Journal of Experimental Diabetes Research, vol. 3, no. 4, pp. 241–245, 2002.
- F. Podestà, G. Romeo, W.-H. Liu et al., “Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro,” American Journal of Pathology, vol. 156, no. 3, pp. 1025–1032, 2000.
- S. Srinivasan, M. J. Stevens, H. Sheng, K. E. Hall, and J. W. Wiley, “Serum from patients with type 2 diabetes with neuropathy induces complement-independent, calcium-dependent apoptosis in cultured neuronal cells,” The Journal of Clinical Investigation, vol. 102, no. 7, pp. 1454–1462, 1998.
- J. W. Russell, K. A. Sullivan, A. J. Windebank, D. N. Herrmann, and E. L. Feldman, “Neurons undergo apoptosis in animal and cell culture models of diabetes,” Neurobiology of Disease, vol. 6, no. 5, pp. 347–363, 1999.
- S. Srinivasan, M. Stevens, and J. W. Wiley, “Diabetic peripheral neuropathy: evidence for apoptosis associated mitochondrial dysfunction,” Diabetes, vol. 49, no. 11, pp. 1932–1938, 2000.
- M. O. Hengartner, “The biochemistry of apoptosis,” Nature, vol. 407, no. 6805, pp. 770–776, 2000.
- R. M. Friedlander, “Apoptosis and caspases in neurodegenerative diseases,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1365–1375, 2003.
- D. R. Green and J. C. Reed, “Mitochondria and apoptosis,” Science, vol. 281, no. 5381, pp. 1309–1312, 1998.
- G. Kroemer, B. Dallaporta, and M. Resche-Rigon, “The mitochondrial death/life regulator in apoptosis and necrosis,” Annual Review of Physiology, vol. 60, pp. 619–642, 1998.
- M. R. Duchen, “Mitochondria in health and disease: perspectives on a new mitochondrial biology,” Molecular Aspects of Medicine, vol. 25, no. 4, pp. 365–451, 2004.
- L. Cai, W. Li, G. Wang, L. Guo, Y. Jiang, and Y. J. Kang, “Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome c-mediated caspase-3 activation pathway,” Diabetes, vol. 51, no. 6, pp. 1938–1948, 2002.
- G. Ma, M. Al-Shabrawey, J. A. Johnson et al., “Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 373, no. 6, pp. 415–427, 2006.
- L. Hinck, P. Van Der Smissen, M. Heusterpreute, I. Donnay, R. De Hertogh, and S. Pampfer, “Identification of caspase-3 anti caspase-activated deoxyribonuclease in rat blastocysts and their implication in the induction of chromatin degradation (but not nuclear fragmentation) by high glucose,” Biology of Reproduction, vol. 64, no. 2, pp. 555–562, 2001.
- A. M. Vincent, M. Brownlee, and J. W. Russell, “Oxidative stress and programmed cell death in diabetic neuropathy,” Annals of the New York Academy of Sciences, vol. 959, pp. 368–383, 2002.
- D. A. Allen, M. M. Yaqoob, and S. M. Harwood, “Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications,” Journal of Nutritional Biochemistry, vol. 16, no. 12, pp. 705–713, 2005.
Copyright © 2008 Iraj Jafari Anarkooli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.